Paperpal Prime Logo

Experimental Hematology and Oncology : Impact Factor & More

eISSN: 2162-3619pISSN: 2162-3619
JournalOpen Access

Key Metrics

CiteScore
8.1
Eigenfactor
0.001 - 0.005
Impact Factor
5 - 10
SJR
Q2Oncology
SNIP
1.39
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Experimental Hematology and Oncology

Experimental Hematology and Oncology Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher BMC
Language English
Frequency Continuous publication
Article Processing ChargesEUR 2590 | USD 2990 | GBP 2290
Publication Time6
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2012
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 6
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC0
OA statementVisit website
View less

Planning to publish in Experimental Hematology and Oncology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Experimental Hematology and Oncology

AAV-delivered miRNA-gated Cre circuits enable programmable gene activation in AFP-active liver tumor models.
  • 8 Aug 2026
  • Experimental hematology & oncology
Cellular adhesion-dependent 3D morphogenesis indicating brain tumor aggressiveness and chemosensitivity in spherical cavity culture.
  • 8 Aug 2026
  • Experimental hematology & oncology
The spatial and multi-omic landscape of Down syndrome leukemogenesis: moving beyond cellular heterogeneity
  • 6 Aug 2026
  • Experimental Hematology & Oncology
Spatially resolved transcriptomic profiling of myelofibrosis spleen reveals compartment specific niche programs
  • 3 Aug 2026
  • Experimental Hematology & Oncology
Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting
  • 3 Aug 2026
  • Experimental Hematology & Oncology
Arsenic trioxide promotes a glue\u2011like interaction to drive STUB1-mediated NPM-ALK degradation in ALK+ ALCL
  • 30 Jul 2026
  • Experimental Hematology & Oncology
AAV-delivered miRNA-gated Cre circuits enable programmable gene activation in AFP-active liver tumor models.
  • 8 Aug 2026
  • Experimental hematology & oncology
Cellular adhesion-dependent 3D morphogenesis indicating brain tumor aggressiveness and chemosensitivity in spherical cavity culture.
  • 8 Aug 2026
  • Experimental hematology & oncology
The spatial and multi-omic landscape of Down syndrome leukemogenesis: moving beyond cellular heterogeneity
  • 6 Aug 2026
  • Experimental Hematology & Oncology
Spatially resolved transcriptomic profiling of myelofibrosis spleen reveals compartment specific niche programs
  • 3 Aug 2026
  • Experimental Hematology & Oncology
Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting
  • 3 Aug 2026
  • Experimental Hematology & Oncology
Arsenic trioxide promotes a glue\u2011like interaction to drive STUB1-mediated NPM-ALK degradation in ALK+ ALCL
  • 30 Jul 2026
  • Experimental Hematology & Oncology

FAQs on Experimental Hematology and Oncology